This patent teaches that tumor stem cells can be extracted population of non-stem cells by selecting for the cells which have activation of the transcription factor LEF/TCF and/or the beta.-catenin pathway.
This patent essentially takes a pathway that is known to be activated in non-malignant sttem cells and simply applies it to malignant stem cells. Some may argue that in light of KSR v Teleflex these types of patents should not even be issued.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.